1. Deferiprone and Gallium-Protoporphyrin Chitogel as an antimicrobial treatment: Preclinical studies demonstrating antimicrobial activity for S. aureus infected cutaneous wounds.
- Author
-
Kennewell TL, Haidari H, Mashtoub S, Howarth GS, Wormald PJ, Cowin AJ, Vreugde S, and Kopecki Z
- Subjects
- Animals, Mice, Staphylococcal Infections drug therapy, Staphylococcal Infections microbiology, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents chemistry, Hydrogels chemistry, Wound Infection drug therapy, Wound Infection microbiology, Skin microbiology, Skin drug effects, Microbial Sensitivity Tests, Anti-Infective Agents pharmacology, Anti-Infective Agents chemistry, Pyridones chemistry, Pyridones pharmacology, Pyridones therapeutic use, Staphylococcus aureus drug effects, Chitosan chemistry, Chitosan pharmacology, Biofilms drug effects, Deferiprone pharmacology, Deferiprone chemistry, Deferiprone therapeutic use, Gallium chemistry, Gallium pharmacology, Wound Healing drug effects, Protoporphyrins pharmacology, Protoporphyrins chemistry
- Abstract
Staphylococcus aureus (S. aureus) is one of the most common wound pathogens with increased resistance towards currently available antimicrobials. S. aureus biofilms lead to increase wound chronicity and delayed healing. Chitosan-dextran hydrogel (Chitogel) loaded with the hydroxypyridinone-derived iron chelator Deferiprone (Def) and the heme analogue Gallium-Protoporphyrin (GaPP) have previously been shown to have antimicrobial effects in clinical sinusitis. In this study, the efficacy of Chitogel loaded with Def, GaPP and a combination of Def and GaPP, were investigated in an S. aureus biofilm infected wound murine model over 10 days of treatment. Bacterial wound burden was monitored daily showing a significant decrease in bacterial bioburden on days 6 and 8 when treated with Def-GaPP Chitogel (log
10 1.0 and 1.2 reduction vs control, respectively). The current study demonstrates that the combination of Def-GaPP delivered in a Chitogel in vivo is not only effective in reducing S. aureus biofilm infection, but also improves cutaneous healing via effects on reduced inflammation, promotion of anti-inflammatory macrophage phenotype and marked early collagen deposition in the wound bed. This delivery platform presents a promising alternative non-toxic, antibacterial, wound-promoting treatment as a novel approach for the management of S. aureus wound infections that warrants further clinical investigation., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Peter J Wormald reports equipment, drugs, or supplies were provided by Chitogel Pty Ltd. Peter J Wormald reports a relationship with Chitogel Pty Ltd that includes: equity or stocks. Peter J Wormald and Sarah Vreudge have patent pending to University of Adelaide., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF